News

ProteLight’s PL-5 was listed in Priority Review Varieties

2015-09-15

National Health and Family Planning Commission of the P.R.C. intend to accelerate the production process of Key innovative new drug manufacture projects, key science and technology projects. The special implementation management office of Key innovative new drug manufacture projects propose to recommend 17 drugs, including ProteLight’s PL-5 as priority review varieties on basis on experts selecting suggestions.

The link of related report:
http://www.moh.gov.cn/qjjys/s7949s/201509/67e8bde6d67b4d90958f16aec4b7754b.shtml

Previous article

Dr. Yuxin Chen and Dr. Hartmut Michel attended the roundtable conference with the theme of “2015 Wuxin Innovation and Entrepreneurship Week”

Next article

Warmly congratulations to establishment of Hartmut Michel Institute of (Jiangyin) Biomedical Research

/news_detail/49.html

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

—

2024-10-26

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-3301 Oral Gel Has Been Granted FDA Approval To Commence Clinical Trials.

■

The publication of a confirmative Phase III clinical study on Peceleganan Spray (project code: PL-5), an innovative antimicrobial peptide developed by ProteLight Pharms, has been released.

■

ProteLight Pharma was selected into the list of “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”

■

Congratulations to the company for passing the ISO9001 quality management system certification

■

Antimicrobial Peptide PL-18 Suppository (First-in-class new drug) of ProteLight Pharma Received Clinical Trial Approval from CDE in China